In abstinent MDMA users the cortisol awakening response is off-set but associated with prefrontal serotonin transporter binding as in non-users

International Journal of Neuropsychopharmacology

Volumn 17, Issue 8, 2014, Pages 1119-1128

  Frokjaer, Vibe Gedsoe ^a   Erritzoe, David ^a   Holst, Klaus Kähler ^a,b   Madsen, Kathrine Skak ^a,c   Fisher, Patrick Macdonald ^a   Madsen, Jacob ^a   Svarer, Claus ^a   Knudsen, Gitte Moos ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Mental Health Services CPH   (Denmark)

Author keywords

5 HTT; Cortisol; DASB; Glucocorticoid; HPA axis; MDMA; PET

Indexed keywords

3 AMINO 4 (2 DIMETHYLAMINOMETHYLPHENYLSULFANYL) BENZONITRILE C 11; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; HYDROCORTISONE; RADIOLIGAND; SEROTONIN; SEROTONIN TRANSPORTER; TRACER; UNCLASSIFIED DRUG; 3-AMINO-4-(2-DIMETHYLAMINOMETHYLPHENYLSULFANYL)BENZONITRILE; ANILINE DERIVATIVE; BIOLOGICAL MARKER; SULFIDE;

ABSTINENCE; ADULT; AGE; AREA UNDER THE CURVE; AROUSAL; ARTICLE; BODY MASS; BOLUS INJECTION; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DRUG BINDING; DRUG USE; FEMALE; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; NEUROIMAGING; NEUROTRANSMISSION; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECEPTOR BINDING; SALIVA ANALYSIS; SEROTONIN RELEASE; AGED; CASE CONTROL STUDY; DIAGNOSTIC USE; ENDOCRINE FUNCTION TEST; FUNCTIONAL NEUROIMAGING; METABOLISM; MIDDLE AGED; SALIVA; SCINTISCANNING; VERY ELDERLY; WAKEFULNESS; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANILINE COMPOUNDS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DRUG USERS; FEMALE; FUNCTIONAL NEUROIMAGING; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PITUITARY-ADRENAL FUNCTION TESTS; POSITRON-EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; SALIVA; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SULFIDES; WAKEFULNESS; YOUNG ADULT;

EID: 84927566558     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145714000066     Document Type: Article

References (47)

1. Adam EK, Doane LD, Zinbarg RE, Mineka S, Craske MG, Griffith JW (2010) Prospective prediction of major depressive disorder from cortisol awakening responses in adolescence. Psychoneuroendocrinology 35:921-931.
2. Ansorge MS, Zhou M, Lira A, Hen R, Gingrich JA (2004) Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306:879-881.
3. Biezonski DK, Meyer JS (2011) The nature of 3,4-Methylenedioxymethamphetamine (MDMA)-induced serotonergic dysfunction: evidence for and against the neurodegeneration hypothesis. Curr Neuropharmacol 9:84-90.
4. Biezonski DK, Piper BJ, Shinday NM, Kim PJ, Ali SF, Meyer JS (2013) Effects of a short-course MDMA binge on dopamine transporter binding and on levels of dopamine and its metabolites in adult male rats. Eur J Pharmacol 701:176-180.
5. Blakely RD, De Felice LJ, Hartzell HC (1994) Molecular physiology of norepinephrine and serotonin transporters. J Exp Biol 196:263-281.
6. Booij SH, Bouma EM, de Jonge P, Ormel J, Oldehinkel AJ (2013) Chronicity of depressive problems and the cortisol response to psychosocial stress in adolescents: the TRAILS study. Psychoneuroendocrinology 38:659-666.
7. Briere FN, Fallu JS, Janosz M, Pagani LS (2012) Prospective associations between meth/amphetamine (speed) and MDMA (ecstasy) use and depressive symptoms in secondary school students. J Epidemiol Community Health 66:990-994.
8. Buchert R, Thomasius R, Petersen K, Wilke F, Obrocki J, Nebeling B, Wartberg L, Zapletalova P, Clausen M (2006) Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users. Eur J Nucl Med Mol Imaging 33:188-199.
9. Chen MC, Joormann J, Hallmayer J, Gotlib IH (2009) Serotonin transporter polymorphism predicts waking cortisol in young girls. Psychoneuroendocrinology 34:681-686.
10. Cohen S, Kamarck T, Mermelstein R (1983) A global measure of perceived stress. J Health Soc Behav 24:385-396.
11. Corchs F, Nutt DJ, Hood S, Bernik M (2009) Serotonin and sensitivity to trauma-related exposure in selective serotonin reuptake inhibitors-recovered posttraumatic stress disorder. Biol Psychiatry 66:17-24.
12. de Win MM, Jager G, Booij J, Reneman L, Schilt T, Lavini C, Olabarriaga SD, den Heeten GJ, van den Brink W (2008) Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain 131:2936-2945.
13. Dmitrieva NO, Almeida DM, Dmitrieva J, Loken E, Pieper CF (2013) A day-centered approach to modeling cortisol: diurnal cortisol profiles and their associations among U.S. adults. Psychoneuroendocrinology.
14. Erritzoe D, Frokjaer VG, Haahr MT, Kalbitzer J, Svarer C, Holst KK, Hansen DL, Jernigan TL, Lehel S, Knudsen GM (2010) Cerebral serotonin transporter binding is inversely related to body mass index. Neuroimage 52:284-289.
15. Erritzoe D, Frokjaer VG, Holst KK, Christoffersen M, Johansen SS, Svarer C, Madsen J, Rasmussen PM, Ramsoy T, Jernigan TL, Knudsen GM (2011) In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users. Arch Gen Psychiatry 68:562-576.
16. Forster GL, Feng N, Watt MJ, Korzan WJ, Mouw NJ, Summers CH, Renner KJ (2006) Corticotropin-releasing factor in the dorsal raphe elicits temporally distinct serotonergic responses in the limbic system in relation to fear behavior. Neuroscience 141:1047-1055.
17. Forster GL, Pringle RB, Mouw NJ, Vuong SM, Watt MJ, Burke AR, Lowry CA, Summers CH, Renner KJ (2008) Corticotropin-releasing factor in the dorsal raphe nucleus increases medial prefrontal cortical serotonin via type 2 receptors and median raphe nucleus activity. Eur J Neurosci 28:299-310.
18. Fries E, Dettenborn L, Kirschbaum C (2009) The cortisol awakening response (CAR): facts and future directions. Int J Psychophysiol 72:67-73.
19. Frokjaer VG, Vinberg M, Erritzoe D, Svarer C, Baare W, Budtz-Joergensen E, Madsen K, Madsen J, Kessing LV, Knudsen GM (2009) High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding. Neuroimage 46:360-366.
20. Frokjaer VG, Erritzoe D, Holst KK, Jensen PS, Rasmussen PM, Fisher PM, Baare W, Madsen KS, Madsen J, Svarer C, Knudsen GM (2013) Prefrontal serotonin transporter availability is positively associated with the cortisol awakening response. Eur Neuropsychopharmacol 23:285-294.
21. Gerra G, Bassignana S, Zaimovic A, Moi G, Bussandri M, Caccavari R, Brambilla F, Molina E (2003) Hypothalamic-pituitary-adrenal axis responses to stress in subjects with 3,4-methylenedioxy-methamphetamine ('ecstasy') use history: correlation with dopamine receptor sensitivity. Psychiatry Res 120:115-124.
22. Gotlib IH, Joormann J, Minor KL, Hallmayer J (2008) HPA axis reactivity: a mechanism underlying the associations among 5-HTTLPR, stress, and depression. Biol Psychiatry 63:847-851.
23. Hashimoto S, Inoue T, Koyama T (1999) Effects of conditioned fear stress on serotonin neurotransmission and freezing behavior in rats. Eur J Pharmacol 378:23-30.
24. Herman JP, Ostrander MM, Mueller NK, Figueiredo H (2005) Limbic system mechanisms of stress regulation: hypothalamo-pituitary-adrenocortical axis. Prog Neuropsychopharmacol Biol Psychiatry 29:1201-1213.
25. Hood SD, Hince DA, Robinson H, Cirillo M, Christmas D, Kaye JM (2006) Serotonin regulation of the human stress response. Psychoneuroendocrinology 31:1087-1097.
26. Hysek CM, Domes G, Liechti ME (2012) MDMA enhances "mind reading" of positive emotions and impairs "mind reading" of negative emotions. Psychopharmacology (Berl) 222:293-302.
27. Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, Suhara T, Suzuki K, Innis RB, Carson RE (2003) Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 23:1096-1112.
28. Innis RB et al. (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-1539.
29. Kim JS, Ichise M, Sangare J, Innis RB (2006) PET imaging of serotonin transporters with [11C]DASB: test-retest reproducibility using a multilinear reference tissue parametric imaging method. J Nucl Med 47:208-214.
30. Kish SJ, Lerch J, Furukawa Y, Tong J, McCluskey T, Wilkins D, Houle S, Meyer J, Mundo E, Wilson AA, Rusjan PM, Saint-Cyr JA, Guttman M, Collins DL, Shapiro C, Warsh JJ, Boileau I (2010) Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain 133:1779-1797.
31. Lanfumey L, Mongeau R, Cohen-Salmon C, Hamon M (2008) Corticosteroid-serotonin interactions in the neurobiological mechanisms of stress-related disorders. Neurosci Biobehav Rev 32:1174-1184.
32. Parrott AC, Lock J, Conner AC, Kissling C, Thome J (2008) Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: prospective neuroendocrine and psychobiological changes. Neuropsychobiology 57:165-180.
33. Pruessner JC, Dedovic K, Pruessner M, Lord C, Buss C, Collins L, Dagher A, Lupien SJ (2010) Stress regulation in the central nervous system: evidence from structural and functional neuroimaging studies in human populations-2008 Curt Richter Award Winner. Psychoneuroendocrinology 35:179-191.
34. Puig MV, Gulledge AT (2011) Serotonin and prefrontal cortex function: neurons, networks, and circuits. Mol Neurobiol 44:449-464.
35. Quarantelli M, Berkouk K, Prinster A, Landeau B, Svarer C, Balkay L, Alfano B, Brunetti A, Baron JC, Salvatore M (2004) Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. J Nucl Med 45:192-201.
36. Quelch DR, Parker CA, Nutt DJ, Tyacke RJ, Erritzoe D (2012) Influence of different cellular environments on [(3)H]DASB radioligand binding. Synapse 66:1035-1039.
37. Reimold M, Knobel A, Rapp MA, Batra A, Wiedemann K, Strohle A, Zimmer A, Schonknecht P, Smolka MN, Weinberger DR, Goldman D, Machulla HJ, Bares R, Heinz A (2011) Central serotonin transporter levels are associated with stress hormone response and anxiety. Psychopharmacology (Berl) 213:563-572.
38. Schule C (2007) Neuroendocrinological mechanisms of actions of antidepressant drugs. J Neuroendocrinol 19:213-226.
39. Sibille E, Lewis DA (2006) SERT-ainly involved in depression, but when? Am J Psychiatry 163:8-11.
40. Sumnall HR, Cole JC (2005) Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: a meta-analysis. J Psychopharmacol 19:84-92.
41. Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugbol S, Frokjaer VG, Holm S, Paulson OB, Knudsen GM (2005) MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage 24:969-979.
42. Urban NB, Girgis RR, Talbot PS, Kegeles LS, Xu X, Frankle WG, Hart CL, Slifstein M, Abi-Dargham A, Laruelle M (2012) Sustained recreational use of ecstasy is associated with altered pre and postsynaptic markers of serotonin transmission in neocortical areas: a PET study with [(1)(1)C]DASB and [(1)(1)C]MDL 100907. Neuropsychopharmacology 37:1465-1473.
43. Vreeburg SA, Hoogendijk WJ, van Pelt J, Derijk RH, Verhagen JC, van Dyck R, Smit JH, Zitman FG, Penninx BW (2009) Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. Arch Gen Psychiatry 66:617-626.
44. Wilhelm I, Born J, Kudielka BM, Schlotz W, Wust S (2007) Is the cortisol awakening rise a response to awakening? Psychoneuroendocrinology 32:358-366.
45. Wilson AA, Ginovart N, Hussey D, Meyer J, Houle S (2002) In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nucl Med Biol 29:509-515.
46. Wolff K, Tsapakis EM, Pariante CM, Kerwin RW, Forsling ML, Aitchison KJ (2012) Pharmacogenetic studies of change in cortisol on ecstasy (MDMA) consumption. J Psychopharmacol 26:419-428.
47. Wust S, Wolf J, Hellhammer DH, Federenko I, Schommer N, Kirschbaum C (2000) The cortisol awakening response-normal values and confounds. Noise Health 2:79-88.